ATAI Beckley Inc (ATAI)

ATAI Beckley Inc. is a clinical-stage biopharmaceutical company focused on researching, developing, and commercializing treatments for mental health conditions. The company operates in the United States, Germany, and Canada and is based in New York, New York. Its pipeline includes BPL-003, an intranasal mebufotenin-based candidate being studied in Phase 2a and Phase 2b trials for treatment-resistant depression and alcohol use disorder; RL-007, an orally bioavailable pro-cognitive neuromodulator in Phase 2b testing for cognitive impairment associated with schizophrenia; and ELE-101 for major depressive disorder. Additional programs include VLS-01 for treatment-resistant depression, EMP-01 for social anxiety disorder, and EGX-A and EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists. The company also has exposure to COMP360 for psilocybin therapy and GRX-917 for anxiety, depression, and other neurological disorders. Founded in 2018, the company was previously known as Atai Beckley N.V. and adopted its current name in December 2025.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.